Qizheng Tibetan Medicine (002287.SZ) released its performance for the first half of the year, with a net profit attributable to the parent company of 3.58 billion yuan, an increase of 10.04%.

Finance APP News, Qizheng Tibetan Medicine (002287.SZ) released its 2025 interim report. The company's operating income was 1.175 billion yuan, a year-on-year increase of 16.36%. The net profit attributable to the shareholders of the listed company was 358 million yuan, a year-on-year increase of 10.04%. The net profit attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 289 million yuan, a year-on-year increase of 27.36%. The basic earnings per share was 0.6756 yuan. In addition, it is proposed to distribute a cash dividend of 2.20 yuan (including tax) to all shareholders for every 10 shares held.